US › Healthcare

Valneva SE ADR (VALN)

US · Healthcare · Biotechnology

$5.61-5.08%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$35.5M

Revenue YoY

-26.5%

Net profit

$-31.7M

EPS

$-0.40

EPS estimate

$-0.28

Net margin

-89.3%

EPS came in at -0.40 against a street estimate of -0.28 — a miss of 42.9%.

Key statistics

Market cap

$536.7M

Forward P/E

3.6

P/B

6.47

Book value

$0.96

EPS (TTM)

$-2.11

52-week high

$12.18

52-week low

$4.75

50-day MA

$6.30

200-day MA

$7.05

Beta

1.26

Analyst view

Analysts rate Valneva SE ADR a buy (3 buy, 0 hold, 1 sell out of 4) with an average price target of $12.25.

Shareholding

Institutions

3.99%

Largest institutional holders

Fund	Stake
Frazier Life Sciences Management, L.P.	2.42%
Vivo Capital, LLC	0.80%
General American Investors Co Inc	0.37%
Millennium Management LLC	0.14%
Wells Fargo & Co	0.08%
Morgan Stanley - Brokerage Accounts	0.06%
Ironwood Investment Management LLC	0.05%
Citadel Advisors Llc	0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Valneva SE ADR — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.